Mylan Launches First Trastuzumab Biosimilar in India - - BioPharm International

ADVERTISEMENT

Mylan Launches First Trastuzumab Biosimilar in India



Mylan, a generic and specialty pharmaceutical company, reported that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India. The product, which will be marketed by Mylan under the brand name Hertraz, is a biosimilar to Roche's Herceptin. Hertraz is indicated for the treatment of HER2-positive metastatic breast cancer and is available in 440 mg and 150 mg.  Hertraz was approved by the Drug Controller General of India.

Trastuzumab is one of the five biologic products Mylan is developing in partnership with Biocon for the global marketplace. Mylan has exclusive commercialization rights for biosimilar trastuzumab in the US, Canada, Japan, Australia, New Zealand, EU, and European Free Trade Association countries. In addition, Mylan has co-exclusive commercialization rights with Biocon for the product in India.

Source: Mylan

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
USP Center in Ghana Receives International Lab Accreditation
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Report Predicts Generics Production Return to US
August 15, 2014
Author Guidelines

Click here